Novartis reports data from trial of IgA nephropathy treatment
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
The companies also plan to collaborate on several early pipeline projects, further technology exploration, and engineering of scalable manufacturing solutions across Novo Nordisk's portfolio
Aims to become a leading global partner for botanical extracts and natural actives in the beauty and personal care market
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial
TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery
New leadership team announced at NATHEALTH Annual General Meeting 2024
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
Subscribe To Our Newsletter & Stay Updated